摘要
目的探讨非小细胞肺癌(NSCLC)组织中DNA切除修复交叉互补基因1(ERCC1)的表达与铂类化疗远期疗效之间的关系及其对患者预后的影响。方法应用免疫组化法对63例NSCLC手术切除石蜡包埋病理标本中ERCC1基因表达进行测定,并将患者的化疗疗效和生存资料与上述指标表达进行比较。结果 NSCLC组织中ERCC1阳性表达率为26.9%;pTNM分期、ERCC1表达为影响术后NSCLC预后的独立因素,ERCC1表达阴性者的术后生存优于表达阳性者;ERCC1表达阴性者术后使用铂类药物辅助化疗有延长生存时间的趋势。结论 ERCC1表达与术后生存呈负相关,可作为术后NSCLC生存预测的指标。
Objective To study the expression of ERCC1 and the correlation with effect of platinum-based adjuvant chemotherapy as well as its impact on prognosis of non-small cell lung cancer（NSCLC） after surgery.Methods Expression of ERCC1 in 63 cases of NSCLC paraffin-embedded pathological specimens were determined by immunohistochemistry method.The association between the ERCC1 expression and response to chemotherapy as well as survival data were analyzed.Results Positive rate of ERCC1 expression in NSCLC was 26.9%.Expression of ERCC1 and pTNM stage were independent determinants to the prognosis of NSCLC after surgery.The survival time in ERCC1 negative group was longer than that in ERCC1 positive group.Patients with negative expression of ERCC1 in NSCLC showed a trend of improved survival time under platinum-based adjuvant chemotherapy.Conclusions ERCC1 can be used as a molecular marker of prognosis in NSCLC after surgery.
出处
《新疆医科大学学报》
CAS
2010年第7期771-773,共3页
Journal of Xinjiang Medical University
基金
新疆医科大学创新基金(2008-3-9)
